Clinical chemistry analyzers play a key role in clinical laboratories for analyzing samples such as blood, serum, and urine for the detection of analytes. Zion Market Research's latest report on the global clinical chemistry analyzers market provides an analysis of the growth of the market through the forecast period 2016-2024.
Certain factors that contribute to the growth of this global market are:
- The growing healthcare expenditure
- Fast growth in the diagnostic market
- Rising prevalence rates of lifestyle disease, including diabetes and obesity
- The rising elderly population
- Increasing need for laboratory automation
- Increasing alertness for preventive healthcare
On the other hand, the high cost, the risk of outcome ambiguity, and the need of trained and qualified professionals are some of the factors that may restrain the market growth.
The report divides the market on the basis of test, product, end-user, and region. The test segment of the market includes renal profile, electrolyte panel, lipid profile, specialty chemicals, basic metabolic panel, thyroid function panel, and liver panel. The product segment is divided into reagents, analyzers, and other products. While the reagent segment of the clinical chemistry analyzer market is sub-segmented into controls, calibrators, standards, and other reagents, the analyzers segment of the market is further divided into very large (2000 Tests/H), large (1200-2000 Tests/H), medium (800-1200 Tests/H), and small (400-800 Test/H).
The end-users of the market are diagnostics laboratories, academic research institutes, hospitals, and other end users. Regionally, the global clinical chemistry analyzer market is classified into Europe, North America, Asia-Pacific, Latin America, and the Middle East & Africa.
Key players in the market include Mindray Medical International Limited, Danaher Corporation, Siemens AG, Roche Diagnostics, Abbott Diagnostics, Ortho-Clinical Diagnostics, ElitechGroup, Thermo Fisher Scientific, Randox Laboratories Ltd., and Horiba.